Skip to main content
Clinical Trials/CTRI/2023/01/049280
CTRI/2023/01/049280
Not yet recruiting
Phase 2

A Prospective Interventional randomized study to assess efficacy of Angiotensin Receptor Nephrilysin Inhibitor (Sacubitril/Valsartan) in right ventricular systolic dysfunction with normal LV functionâ??

MDM hospitalDr SN Medical College0 sites0 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
MDM hospitalDr SN Medical College
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
MDM hospitalDr SN Medical College

Eligibility Criteria

Inclusion Criteria

  • Patients of Right Ventricular systolic dysfunction with Normal Left ventricular systolic function as diagnosed by transthoracic echocardiography parameters such as TAPSE( \<16mm), PAsP( \>25mm Hg), tricuspid annular velocity( \<10 cm/sec), Fractional area change( \<35%) and blood markers such as NT\-proBNp( \>400pg/ml).

Exclusion Criteria

  • 1\.Patients with LVEF \<50%
  • 2\.Pregnancy
  • 3\. Severe hepatic impairment (Child. Pugh C)
  • 4\.Severe renal imapairment (eGFR \<30 ml/min/1\.73m2\)
  • Hypersensitivity to any component of the product
  • A prior history of angioedema due to an ACEI or ARB

Outcomes

Primary Outcomes

Not specified

Similar Trials